Cyclopamine

For research use only. Not for use in humans.

目录号:S1146 别名: 11-deoxojervine 中文名称:环巴胺

Cyclopamine Chemical Structure

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cyclopamine发表文献57篇:

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnXb|ZVUUN3ME21Mlg3PjZizszN NH;nZldUSU6JRWK=
DOHH-2 NIn1VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTlwM{W2PFkh|ryP MULTRW5ITVJ?
no-10 M2n5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXxSFBnUUN3ME25MlkxOzlizszN M3Xkc3NCVkeHUh?=
LS-513 MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fB[GlEPTB;MUGuN|U1PyEQvF2= NH7xbI9USU6JRWK=
ALL-PO M3yyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQfpdKSzVyPUGxMlc4OzRizszN M4jRfXNCVkeHUh?=
8-MG-BA MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLkXmt7UUN3ME2xN{4yOTJ|IN88US=> NXmyOmpmW0GQR1XS
RPMI-8402 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITsVYFKSzVyPUG1Mlg2OzdizszN NILzR2FUSU6JRWK=
EoL-1-cell NH;Q[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4SWlEPTB;MUiuOVk1QCEQvF2= MnrYV2FPT0WU
NALM-6 NGG3dm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvJNIRSUUN3ME2xPU4xOTZ5IN88US=> M3jDbHNCVkeHUh?=
DEL MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJyLkG0O|Eh|ryP NUS2N2J{W0GQR1XS
SR NU\2PZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXBdI1KSzVyPUKzMlY4OTVizszN NGjwc4xUSU6JRWK=
697 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[zbnQyUUN3ME2yOk43OTV3IN88US=> MV3TRW5ITVJ?
COLO-829 M4Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW5RnlrUUN3ME2yOk45PDh|IN88US=> MmrZV2FPT0WU
EVSA-T MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vxSWlEPTB;MkeuOVU3OSEQvF2= M3LrOXNCVkeHUh?=
ATN-1 NU\NXnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrySoNKSzVyPUOxMlI{OjlizszN NX7UW4FpW0GQR1XS
L-363 NVG3NW52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf5TWM2OD1|MT63OFYyKM7:TR?= NEnvTVZUSU6JRWK=
LAMA-84 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN{LkWyNVEh|ryP NYPERlRYW0GQR1XS
NOS-1 NHuybWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\B[41KSzVyPUO0MlI6PTZizszN MkG3V2FPT0WU
BB30-HNC NVHHWHhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TBRWlEPTB;M{SuN|MxPiEQvF2= NYjWNZBRW0GQR1XS
BC-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37tTGlEPTB;M{euPVc1PiEQvF2= MYrTRW5ITVJ?
IST-SL2 NXizR4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfDcVdKSzVyPUO4MlIzPCEQvF2= MWfTRW5ITVJ?
D-392MG NIX5WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRyLkKyNVUh|ryP NETxXHJUSU6JRWK=
no-11 NF\nbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHXNndKUUN3ME20NE42PTJzIN88US=> NIjXSXNUSU6JRWK=
LC4-1 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGXWlEPTB;NECuPFcyPiEQvF2= MmTyV2FPT0WU
A388 M{nnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR{LkW4OFgh|ryP M2rDZXNCVkeHUh?=
NTERA-S-cl-D1 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnDSIJKSzVyPUSyMlcxPzRizszN NVHzem15W0GQR1XS
CESS MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[1OmlEPTB;NESuNlI{OiEQvF2= MmjXV2FPT0WU
RS4-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR7LkC5N|gh|ryP NYrh[lRzW0GQR1XS
MS-1 NVrhWZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNTWM2OD13MD65N|UyKM7:TR?= NVWxd3lYW0GQR1XS
CTV-1 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTVzLkC3OEDPxE1? M4nSfXNCVkeHUh?=
D-502MG MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1b|hSUUN3ME21NU43OjdzIN88US=> NYfOfnZGW0GQR1XS
ML-2 NU\PRo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXUc|dUUUN3ME21Nk46OTl3IN88US=> NESyTJdUSU6JRWK=
SK-NEP-1 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFPVZnUUN3ME21N{4{QTJ|IN88US=> Mn3EV2FPT0WU
LOXIMVI NXnXVVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XvW2lEPTB;NUOuOVg5PCEQvF2= NFXITndUSU6JRWK=
DJM-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jMbWlEPTB;NU[uN|M6OSEQvF2= NGS5WnBUSU6JRWK=
GI-1 NEPuSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofQTWM2OD13Nj62NVQ6KM7:TR?= M3\nXHNCVkeHUh?=
IST-MES1 M1;Y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZyLkW0PVMh|ryP NIHjbWFUSU6JRWK=
MV-4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTZyLk[1N|gh|ryP M1nn[nNCVkeHUh?=
OVCAR-4 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDYTWM2OD14Mz61OlU4KM7:TR?= M3L5Z3NCVkeHUh?=
KE-37 M1PLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjWTWM2OD14Nj6yOlY5KM7:TR?= MnfmV2FPT0WU
D-542MG M2X5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrEdnZKSzVyPU[4MlQyOzVizszN M{PjV3NCVkeHUh?=
MHH-PREB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvuTWM2OD15Mj64OFQyKM7:TR?= NUn2UppCW0GQR1XS
MRK-nu-1 NH35NoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD15Mz60O|A2KM7:TR?= NH\ORohUSU6JRWK=
D-247MG MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTd|LkW0OFIh|ryP NGj3eGVUSU6JRWK=
OCI-AML2 NF7FWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;YTWM2OD15Nj65N|Y6KM7:TR?= NYrYNmFWW0GQR1XS
LP-1 NGLjSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPoTWM2OD16Mj64O|MyKM7:TR?= NHTXV3NUSU6JRWK=
HCC1599 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTh2LkK4N|ch|ryP MYLTRW5ITVJ?
KARPAS-45 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XKPGlEPTB;OESuOlk6OiEQvF2= Mo\5V2FPT0WU
BE-13 NH7xcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfnbYE3UUN3ME25PU4xPDd5IN88US=> M2LVd3NCVkeHUh?=
GCIY NEj5foRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTl7LkC5OVQh|ryP MmH2V2FPT0WU
BV-173 M4jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37mV2lEPTB;MUCwMlMzPSEQvF2= MojhV2FPT0WU
LB2518-MEL NVH6Sm1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrwTWM2OD1zMECuO|g6KM7:TR?= NHLGdpZUSU6JRWK=
KS-1 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFyMT62N|kh|ryP MYrTRW5ITVJ?
MOLT-16 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHZTWM2OD1zMESuPVg3KM7:TR?= NY\N[WxqW0GQR1XS
NCI-H1770 NVXFdoRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFyOD63PFQh|ryP NFXB[nlUSU6JRWK=
NCI-H82 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFzMD65O|Yh|ryP MXzTRW5ITVJ?
NCCIT M3;yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTrfIxKSzVyPUGxNk42OjlizszN MYfTRW5ITVJ?
KALS-1 M3HXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFzNT65OFEh|ryP MV;TRW5ITVJ?
LB2241-RCC MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXncpFKSzVyPUGxOk43PzlizszN NH\oOY5USU6JRWK=
HH M{PIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\HUIN{UUN3ME2xNVcvOzl3IN88US=> NU\KWm9HW0GQR1XS
HD-MY-Z NEHmblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPlTZpVUUN3ME2xNVgvPDh6IN88US=> M4LpNnNCVkeHUh?=
EB-3 NWT5WJVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rueWlEPTB;MUKzMlA6PCEQvF2= M2XlPXNCVkeHUh?=
BL-70 M3G2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF{Mz6xNlch|ryP NXG0OYd6W0GQR1XS
K-562 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDsTWM2OD1zMk[uNlQ2KM7:TR?= M4\aUXNCVkeHUh?=
HT-144 NHKzZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPXTWM2OD1zM{OuNVY1KM7:TR?= MVrTRW5ITVJ?
PF-382 M4\hV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSzcoRVUUN3ME2xN|QvOzZzIN88US=> MWPTRW5ITVJ?
RPMI-8226 M1\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnHeYpPUUN3ME2xN|UvODR3IN88US=> MkG4V2FPT0WU
NCI-H1355 NFLkfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zWU2lEPTB;MUO1MlU5PyEQvF2= M2DKTXNCVkeHUh?=
LXF-289 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\IRWlEPTB;MUO5Mlc5OSEQvF2= M3qxRnNCVkeHUh?=
NCI-H69 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOzTWM2OD1zNEKuPVMzKM7:TR?= M3\N[XNCVkeHUh?=
SK-MEL-1 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF2Nz6xN{DPxE1? MnnkV2FPT0WU
KARPAS-299 M3S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[2TWM2OD1zNEmuNVIh|ryP MX7TRW5ITVJ?
GB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly2TWM2OD1zNEmuN|IzKM7:TR?= MlfiV2FPT0WU
CMK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLncZdKSzVyPUG0PU42OTVizszN MVzTRW5ITVJ?
MPP-89 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrrT5FrUUN3ME2xOVYvODN3IN88US=> MVvTRW5ITVJ?
KU812 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PVTWlEPTB;MU[xMlkxOiEQvF2= MUTTRW5ITVJ?
REH MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXiUJEzUUN3ME2xOlIvOTJ3IN88US=> NVvJ[ldmW0GQR1XS
NEC8 M3jNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF4NT6wNlYh|ryP M3vnXHNCVkeHUh?=
KP-N-YS M2fWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnZTWM2OD1zNkiuN|k2KM7:TR?= MVvTRW5ITVJ?
Ramos-2G6-4C10 NHfkWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvqTWM2OD1zNkmuPVE2KM7:TR?= MmLoV2FPT0WU
Becker M3yzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r2U2lEPTB;MUe0MlE5KM7:TR?= MnrKV2FPT0WU
LB647-SCLC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4mzSWlEPTB;MUe1Mlg1PSEQvF2= NU\YSG1NW0GQR1XS
LU-139 M3zvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TVb2lEPTB;MUe4MlAyQSEQvF2= M3PUSHNCVkeHUh?=
QIMR-WIL NWTtVGt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW2TWM2OD1zN{muOlQ3KM7:TR?= MVnTRW5ITVJ?
NCI-H1395 NIjXUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPtTpNVUUN3ME2xO|kvQTl4IN88US=> MnK3V2FPT0WU
NOMO-1 NVLSOndzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF6Mj64OUDPxE1? M3rzVXNCVkeHUh?=
GI-ME-N NYrhTXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF6Nz65Olkh|ryP M4e4VnNCVkeHUh?=
KMS-12-PE NYL3[mVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlviTWM2OD1zOEmuNlc{KM7:TR?= M4q0NnNCVkeHUh?=
Daudi M1T1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33kW2lEPTB;MUmxMlEzQCEQvF2= M3m3enNCVkeHUh?=
LB996-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7BV2lKSzVyPUG5NU43QTlizszN NYnSPGF6W0GQR1XS
NCI-H2107 M1XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPiXopKSzVyPUG5N{44OzlizszN NXzHT|lDW0GQR1XS
SK-PN-DW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF7ND63NVkh|ryP NHTidVhUSU6JRWK=
MC-CAR NFrJc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3PHh2UUN3ME2yNFIvOjV|IN88US=> MlTTV2FPT0WU
SNB75 M4nlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G4RmlEPTB;MkKxMlk1KM7:TR?= NHrqOXdUSU6JRWK=
ES4 M4T6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLhR2loUUN3ME2yNlMvPzh|IN88US=> MmP3V2FPT0WU
KARPAS-422 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nZbmlEPTB;MkK4MlM2OiEQvF2= MVvTRW5ITVJ?
NCI-H1648 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD1{MkmuOFg6KM7:TR?= NG\uempUSU6JRWK=
ES6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3RZRKSzVyPUKzPU41OyEQvF2= M2LvOHNCVkeHUh?=
KNS-81-FD NVTD[pRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTWTWM2OD1{NEGuNVk4KM7:TR?= MXLTRW5ITVJ?
JAR NXHGeW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDiR4E5UUN3ME2yOVYvOjJ3IN88US=> MVzTRW5ITVJ?
NB1 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4MD61NVYh|ryP NUDZeZM{W0GQR1XS
D-336MG M2DFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzWVlKSzVyPUK2NE43QThizszN NUHIS|dkW0GQR1XS
BC-3 NFP6e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LuW2lEPTB;Mk[1MlE4QCEQvF2= NH\Qb2FUSU6JRWK=
HCC2218 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ4Nj60NVUh|ryP MkXPV2FPT0WU
TE-9 NE\kOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULMelBPUUN3ME2yOlYvPjJ5IN88US=> MXPTRW5ITVJ?
LB1047-RCC M2TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ4Nj63OVMh|ryP NYjs[oxJW0GQR1XS
CTB-1 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHJTWM2OD1{NkmuPVc{KM7:TR?= MVPTRW5ITVJ?
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnKTWM2OD1{N{Gg{txO NH3IV49USU6JRWK=
ST486 NE[wdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqTWM2OD1{N{euOFEzKM7:TR?= NH\m[HFUSU6JRWK=
HCC1187 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1{OEKuPFEyKM7:TR?= NFraVpVUSU6JRWK=
NCI-SNU-16 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LN3VKSzVyPUK4OE4zPDhizszN NFixfmhUSU6JRWK=
COR-L279 M2PnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ7MT61PFQh|ryP M2KxSHNCVkeHUh?=
ES8 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHlR4lKUUN3ME2yPVQvOTh{IN88US=> MXLTRW5ITVJ?
U-698-M NHWycZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPRRlltUUN3ME2yPVgvOjR|IN88US=> NYixVJVnW0GQR1XS
HEL MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNyOT6xOFkh|ryP M4XMeHNCVkeHUh?=
KINGS-1 M3j3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r4VmlEPTB;M{GwMlY4PCEQvF2= M2fFfHNCVkeHUh?=
KY821 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLrbodKSzVyPUOzOk42QTVizszN NILmRWdUSU6JRWK=
MZ1-PC NXnNd|lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN2NT62NVgh|ryP NUX3bpFmW0GQR1XS
LS-411N M3;zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTBTWM2OD1|NUSuOlYh|ryP MmDEV2FPT0WU
SIG-M5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nr[GlEPTB;M{W5Mlc5OiEQvF2= NUHUTpJHW0GQR1XS
HT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HjSmlEPTB;M{[3MlcyOSEQvF2= MWPTRW5ITVJ?
HC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN4Nz63PFch|ryP NYjpcoVSW0GQR1XS
NCI-H1694 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD1|N{KuPVM1KM7:TR?= MoTnV2FPT0WU
BB65-RCC M1TNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj0NI1KSzVyPUO3Ok4zPDVizszN MYfTRW5ITVJ?
HAL-01 NF7RWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDaXpVvUUN3ME2zO|kvQDN6IN88US=> M2rXdnNCVkeHUh?=
ARH-77 NIPGUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTTTWM2OD1|OUSuNFA5KM7:TR?= NVfxTXJVW0GQR1XS
MZ7-mel MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfwTWM2OD1|OUeuNlM{KM7:TR?= MVzTRW5ITVJ?
SIMA MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzT2lEPTB;NECzMlk{OyEQvF2= Ml;IV2FPT0WU
DG-75 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRzNT62PVgh|ryP MojQV2FPT0WU
HUTU-80 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLyO4xEUUN3ME20NVkvOTh3IN88US=> M2HpSnNCVkeHUh?=
KNS-42 NWjMS4d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR{NT64NVUh|ryP MnnzV2FPT0WU
SH-4 NVTEc5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof3TWM2OD12MkeuOVY2KM7:TR?= NFy2VYpUSU6JRWK=
L-540 M2TZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv1NYFKSzVyPUSzNU4xOzFizszN M3PUcnNCVkeHUh?=
NB10 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTR2MT6yN|Qh|ryP NFfPSZJUSU6JRWK=
ES1 NHLXXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfCZ2U3UUN3ME20OVIvPzV|IN88US=> NYLDd4JFW0GQR1XS
KMOE-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHxdHNKSzVyPUS1Ok44OTFizszN MVHTRW5ITVJ?
MC116 M3nYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvkeWJKSzVyPUS1PE4yOTZizszN NX23[HJZW0GQR1XS
RCC10RGB NUTwNXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXU2lEPTB;NE[wMlAxPSEQvF2= NHTZXIhUSU6JRWK=
RL95-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR4MD6yN|ch|ryP M3zMenNCVkeHUh?=
Raji M2DhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\SPXFKSzVyPUS2PE4yPDNizszN NFHTc3hUSU6JRWK=
CAS-1 NYDNVXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\aNGlEPTB;NEeyMlA4OyEQvF2= NXmyVXZoW0GQR1XS
Calu-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkZ2lEPTB;NEe1MlI3PSEQvF2= MX;TRW5ITVJ?
KG-1 NWLMVnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nxN2lEPTB;NEe4MlQ1KM7:TR?= M{OxT3NCVkeHUh?=
LB771-HNC M1HOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR6Mj6yN|Ih|ryP M3TiZnNCVkeHUh?=
ACN M17vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrbWlEPTB;NEmzMlU6QSEQvF2= NV35XZlEW0GQR1XS
KM12 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjr[|V7UUN3ME20PVYvPTh7IN88US=> M3fzN3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
- 合并
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
DMSO Insoluble
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
储存条件 粉状
溶于溶剂
别名 11-deoxojervine

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID